| Q52403779 | A microcomputer program to determine the precision of elimination rate constant and half-life estimates when sampling time is short. |
| Q28369049 | A new approach for early assessment of the epileptogenic potential of quinolones |
| Q43815742 | A pharmacokinetic/pharmacodynamic approach to show that not all fluoroquinolones exhibit similar sensitivity toward the proconvulsant effect of biphenyl acetic acid in rats |
| Q43456426 | A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin. |
| Q46869315 | A simple and sensitive liquid chromatography-tandem mass spectrometry assay for the quantification of ertapenem in microdialysate |
| Q50997275 | A survey on the use of gentamicin in infective endocarditis. |
| Q39693073 | Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. |
| Q52082687 | Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats. |
| Q40585826 | Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. |
| Q40334778 | Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry |
| Q41284108 | Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam. |
| Q41830402 | Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 3. Tobramycin. |
| Q42407634 | Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir Carboxylate |
| Q33798218 | Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. |
| Q33798554 | Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin |
| Q44388488 | Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. |
| Q48336043 | Brain microdialysis distribution study of cefotaxime in a patient with traumatic brain injury |
| Q42576946 | Brain microdialysis study of meropenem in two patients with acute brain injury |
| Q45843654 | Characterization of colistin tissue pharmacokinetics by microdialysis. |
| Q38814073 | Ciprofloxacin-Loaded Inorganic-Organic Composite Microparticles To Treat Bacterial Lung Infection. |
| Q43219296 | Colistin distribution in the peritoneal fluid of a patient with severe peritonitis. |
| Q37944305 | Colistin pharmacokinetics: the fog is lifting |
| Q61895432 | Comparative Cerebrospinal Fluid Diffusion of Imipenem and Meropenem in Rats |
| Q34597749 | Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. |
| Q61895410 | Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use |
| Q54356118 | Convulsions and apnoea in a patient infected with New Delhi metallo-β-lactamase-1 Escherichia coli treated with colistin. |
| Q52238784 | Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats. |
| Q28550711 | Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling |
| Q44645929 | Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats |
| Q61895465 | Dose-dependent bioavailability and metabolism of salicylamide in dogs |
| Q43052340 | Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses |
| Q61895434 | Effect of Tamoxifen on the Pharmacokinetics of Theophylline in Rats |
| Q44897082 | Effect of experimentally induced hypovolemia on ertapenem tissue distribution using microdialysis in rats |
| Q61895441 | Effect of ponsinomycin on cyclosporin pharmacokinetics |
| Q61895440 | Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine |
| Q61895439 | Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally |
| Q38536209 | Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent. |
| Q34528991 | Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules |
| Q44755737 | Extension of the isobolographic approach to interactions studies between more than two drugs: illustration with the convulsant interaction between pefloxacin, norfloxacin, and theophylline in rats |
| Q54457367 | Factors affecting nitroxide reduction in ascorbate solution and tissue homogenates. |
| Q61895421 | Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery |
| Q39976809 | Formulation of rifampicin-cyclodextrin complexes for lung nebulization |
| Q44852902 | Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus |
| Q41639978 | High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate |
| Q43908872 | Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats |
| Q51625689 | Impact of colistin sulfate treatment of broilers on the presence of resistant bacteria and resistance genes in stored or composted manure. |
| Q51605837 | Impact of two different colistin dosing strategies on healthy piglet fecal microbiota. |
| Q31876529 | In situ nasal absorption of midazolam in rats. |
| Q40839217 | In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. |
| Q44292514 | In vitro comparative studies of two marketed transdermal nicotine delivery systems: Nicopatch and Nicorette |
| Q61895433 | Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity |
| Q46438449 | Investigation of oral bioavailability and brain distribution of the Ind(8)-Val conjugate of indinavir in rodents. |
| Q49151601 | Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat. |
| Q43103052 | Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. |
| Q44465308 | LC-MS/MS determination of the HIV-1 protease inhibitor indinavir in brain and testis of mice. |
| Q40668041 | Lack of effect of experimental hypovolemia on imipenem muscle distribution in rats assessed by microdialysis |
| Q61895417 | Lack of effect of extracorporeal membrane oxygenation on tigecycline pharmacokinetics |
| Q42041579 | Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers |
| Q61895451 | Lack of effect of ponsinomycin on the plasma pharmacokinetics of theophylline |
| Q42445807 | Lung microdialysis study of levofloxacin in rats following intravenous infusion at steady state. |
| Q37544593 | Metronidazole and hydroxymetronidazole central nervous system distribution: 1. microdialysis assessment of brain extracellular fluid concentrations in patients with acute brain injury. |
| Q41907570 | Metronidazole and hydroxymetronidazole central nervous system distribution: 2. cerebrospinal fluid concentration measurements in patients with external ventricular drain. |
| Q38864274 | Microdialysis as a way to measure antibiotics concentration in tissues |
| Q37026552 | Microdialysis study of cefotaxime cerebral distribution in patients with acute brain injury. |
| Q45790613 | Microdialysis study of imipenem distribution in muscle and lung extracellular fluids of infected rats |
| Q34680635 | Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of Acinetobacter baumannii-infected rats |
| Q42839574 | Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats |
| Q41902868 | Microdialysis study of imipenem distribution in the intraperitoneal fluid of rats with or without experimental peritonitis. |
| Q42099923 | Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis |
| Q46282220 | Microdialysis study of meropenem cerebral distribution in patients with acute brain injury. |
| Q42849250 | Nefopam pharmacokinetics in patients with end-stage renal disease. |
| Q30856181 | New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. |
| Q40834120 | Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting. |
| Q43181780 | Norfloxacin blood-brain barrier transport in rats is not affected by probenecid coadministration |
| Q61895456 | Ofloxacin pharmacokinetics in renal failure |
| Q43075165 | P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. |
| Q51133313 | Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies. |
| Q42045873 | Pharmacokinetic modeling of free amoxicillin concentrations in rat muscle extracellular fluids determined by microdialysis |
| Q39471040 | Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats |
| Q42551258 | Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of pefloxacin and norfloxacin in rats. |
| Q39755517 | Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats. |
| Q35042172 | Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. |
| Q44911076 | Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia. |
| Q53772759 | Pharmacokinetic/pharmacodynamic studies in the CMI. |
| Q46455184 | Pharmacokinetics and metabolic fate of two nitroxides potentially useful as contrast agents for magnetic resonance imaging |
| Q53217740 | Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys. |
| Q59263368 | Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock |
| Q43085379 | Pharmacokinetics of daptomycin in a patient with severe renal failure not receiving dialysis |
| Q41876999 | Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. |
| Q44481432 | Pharmacokinetics of oral cefatrizine in patients with impaired renal function. |
| Q61895437 | Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers |
| Q47865489 | Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: a study in Africa |
| Q44241522 | Pharmacokinetics of two prototype nitroxide spin labels for contrast enhancement in magnetic resonance imaging |
| Q42163294 | Photodegradation study of a new activator of the cystic fibrosis chloride channel, the 6-hydroxy-10-chlorobenzo[c]quinolizinium chloride (MPB-07). |
| Q61895436 | Plasma levels of oxybutynine chloride in children |
| Q40429440 | Population Pharmacokinetics of Amitriptyline After Intrathecal, Epidural, and Intravenous Administration in Sheep |
| Q36644676 | Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis. |
| Q61895463 | Potential Radiosensitizing Effectin Vivoof Nitroxyl Spin Labels |
| Q41189508 | Pulmonary delivery of pyrazinamide-loaded large porous particles. |
| Q51196945 | Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. |
| Q39788312 | Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model |
| Q61719291 | Removal of colistin during intermittent haemodialysis in two critically ill patients |
| Q41228295 | Saturable rate of cefatrizine absorption after oral administration to humans |
| Q40325816 | Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2. |
| Q41997254 | Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. |
| Q42197569 | Specific and non-specific contrast media for MRI of tumors. Experimental study of human breast carcinoma |
| Q61895444 | Steady-state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation |
| Q61719294 | Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia |
| Q46678355 | Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice |
| Q61895447 | [Influence of food intake on the bioavailability of ponsinomycin administered in a syrup form] |
| Q61895449 | [Pharmacokinetics of ponsinomycin administered in a syrup form in single 400-800 and 1200 mg doses in healthy volunteers] |
| Q61895442 | [Pharmacokinetics of ponsinomycine with repeated ingestion in healthy volunteers] |
| Q61895452 | [Pharmacokinetics of sulindac in aged patients presenting with inflammatory joint disease] |
| Q61895462 | [Physiologic compatibility of compartment models used in pharmacokinetics] |